AAV-GUCY2D Gene Therapy

N/A

Report date: 2025/03/14 16:46:58

Base Information

Drug NameAAV-GUCY2D Gene Therapy
Drug Alias NameGUCY2D/PDE6 beta gene replacement therapy (MeiraGTx)AAV-GUCY2D gene therapy (MeiraGTx)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionPhosphodiesterase 6 stimulantsRetinal guanylyl cyclase 1 gene transference
TargetsRetinal guanylyl cyclase 1Phosphodiesterase 6
Therapy Area/IndicationsCone DystrophyRetinal Dysplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMeiragtx Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMeiragtx Ltd
Inactive CompaniesN/A
Active IndicationsCone DystrophyRetinal Dysplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A